Holen Sie sich die Stockscreener-App
7.65
0.33%
-0.00
Handel nachbörslich:
7.50
-0.15
-1.96%
Schlusskurs vom Vortag:
$7.65
Offen:
$7.69
24-Stunden-Volumen:
1.39M
Relative Volume:
0.99
Marktkapitalisierung:
$664.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-3.5253
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+1.94%
1M Leistung:
+22.39%
6M Leistung:
-3.24%
1J Leistung:
-62.22%
1-Tages-Spanne:
$7.475
$7.755
1-Wochen-Bereich:
$6.95
$7.80
52-Wochen-Spanne:
$5.41
$21.57
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.65 | 649.24M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Using RSI to spot recovery in Kura Oncology Inc.Exit Point & Fast Gaining Stock Strategy Reports - Newser
Volume spikes in Kura Oncology Inc. stock – what they meanWeekly Market Summary & Free Safe Entry Trade Signal Reports - Newser
Tools to assess Kura Oncology Inc.’s risk profileWeekly Market Outlook & Weekly High Return Stock Opportunities - Newser
What data driven models say about Kura Oncology Inc.’s future2025 Year in Review & Risk Managed Investment Entry Signals - Newser
Published on: 2025-08-19 23:46:42 - Newser
Comparing Kura Oncology Inc. in custom built stock radarsWeekly Investment Recap & Weekly Breakout Stock Alerts - Newser
What does recent volatility data suggest for Kura Oncology Inc.2025 Price Targets & Entry Point Confirmation Alerts - Newser
Why Kura Oncology Inc. is moving todayJuly 2025 Institutional & Weekly High Potential Stock Alerts - Newser
Kura Oncology Inc (KURA Stock: A Sea of Opportunity - investchronicle.com
Kura Oncology Gains 32%, Insider Trades Reap Benefit - simplywall.st
Chart based analysis of Kura Oncology Inc. trendsJuly 2025 Retail & Free High Return Stock Watch Alerts - Newser
Analyzing Kura Oncology Inc. with multi timeframe charts2025 Buyback Activity & Target Return Focused Picks - Newser
What high frequency data says about Kura Oncology Inc.2025 Major Catalysts & Safe Capital Growth Trade Ideas - Newser
Order flow analysis tools used on Kura Oncology Inc.Earnings Risk Summary & Real-Time Volume Analysis Alerts - Newser
Kura Oncology (NASDAQ:KURA) Shares Gap Up – Still a Buy? - Defense World
Is Kura Oncology Inc. stock entering bullish territoryTreasury Yields & Long-Term Growth Plans - Newser
Wall Street Zen Upgrades Kura Oncology (NASDAQ:KURA) to “Hold” - Defense World
Using Bollinger Bands to evaluate Kura Oncology Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - Newser
What makes Kura Oncology Inc. stock price move sharply2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser
CEO Buy-In and Analyst Optimism at Kura Oncology: A Strategic Opportunity in Oncology Innovation - AInvest
Quant Strategy Flags Kura Oncology Inc. for EntryMarket Performance Recap & Safe Swing Trade Setup Alerts - metal.it
How hedge fund analytics apply to Kura Oncology Inc. stockMarket Trend Report & Verified Stock Trade Ideas - Newser
Kura Oncology Inc. stock chart pattern explainedJuly 2025 Final Week & AI Driven Stock Movement Reports - Newser
Kura Oncology Shares Rise After CEO Buys Company Shares - MarketScreener
Why Kura Oncology (KURA.O) Spiked 14% on a Quiet Day — A Technical Deep Dive - AInvest
Kura Oncology Surges 13.18%—What's Really Behind the Intraday Move? - AInvest
Multi asset correlation models including Kura Oncology Inc.July 2025 Sector Moves & Daily Volume Surge Signals - Newser
US Bancorp DE Acquires 17,523 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s CEO Makes a Bold Move with Significant Stock Purchase - TipRanks
Price Consolidation Hints at Upcoming Move in Kura Oncology Inc.2025 Fundamental Recap & Weekly Setup with ROI Potential - 선데이타임즈
JMP Securities Lowers Kura Oncology Price Target to $24, Maintains Market Outperform Rating - AInvest
Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold? - AInvest
JMP Securities Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology’s Earnings Call: Progress Amidst Challenges - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Kura Oncology Inc. stock attracts strong analyst attentionDouble in 10 Days Stock Ideas - newsyoung.net
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Nigeria
Wedbush Has Bearish Forecast for Kura Oncology Q1 Earnings - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
JMP Securities Maintains Market Outperform on Kura Oncology with New PT of $24 - AInvest
Kura Oncology stock price target lowered to $24 at Citizens JMP - Investing.com Canada
What candlestick patterns are forming on Kura Oncology Inc.Free Pattern Detection for Entry Confirmation - Newser
Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Kura Oncology Reports Q2 2025 Earnings: Key Takeaways - AInvest
Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru
How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser
Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest
Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks
Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast By Investing.com - Investing.com South Africa
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kura Oncology Inc-Aktie (KURA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WILSON TROY EDWARD | President and CEO |
Aug 13 '25 |
Buy |
6.64 |
13,494 |
89,623 |
50,968 |
| Bair Teresa Brophy | Chief Legal Officer |
May 19 '25 |
Sale |
5.96 |
1,559 |
9,292 |
107,948 |
| FORD KATHLEEN | Chief Operating Officer |
May 19 '25 |
Sale |
6.28 |
1,558 |
9,777 |
21,367 |
1.34%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):